{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-26-000014","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.314036+00:00","generated_at":"2026-05-16T01:14:00.449217+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"GeneDx Q4 revenue $121M, +27% YoY; exome/genome +32%; reaffirms FY2026 guidance $540-555M","bullets":["Q4 revenue $121M (+27% YoY); exome/genome revenue $104M (+32%, or +42% ex one-time).","Q4 exome/genome volume 27,761 (+34.3% YoY); adjusted gross margin 71%.","FY2025 revenue $427.5M (+41%); adjusted net income $41.8M vs $9.4M prior year.","Reaffirmed FY2026 revenue guidance $540-555M with 33-35% exome/genome volume growth.","Cash $172.3M; Q4 operating cash flow $5.1M; issued 147,583 shares via ATM netting $21.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-26-000014","json":"https://secwatch.observer/filing/0001818331-26-000014.json","markdown":"https://secwatch.observer/filing/0001818331-26-000014.md","text":"https://secwatch.observer/filing/0001818331-26-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833126000014/0001818331-26-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833126000014/wgs-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:14:00.449217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}